CN110840916A - Application of composition of donkey-hide gelatin and new donkey-hide gelatin in preparation of antioxidant drugs - Google Patents
Application of composition of donkey-hide gelatin and new donkey-hide gelatin in preparation of antioxidant drugs Download PDFInfo
- Publication number
- CN110840916A CN110840916A CN201911221783.5A CN201911221783A CN110840916A CN 110840916 A CN110840916 A CN 110840916A CN 201911221783 A CN201911221783 A CN 201911221783A CN 110840916 A CN110840916 A CN 110840916A
- Authority
- CN
- China
- Prior art keywords
- donkey
- hide gelatin
- new
- composition
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010010803 Gelatin Proteins 0.000 title claims abstract description 60
- 229920000159 gelatin Polymers 0.000 title claims abstract description 60
- 239000008273 gelatin Substances 0.000 title claims abstract description 60
- 235000019322 gelatine Nutrition 0.000 title claims abstract description 60
- 235000011852 gelatine desserts Nutrition 0.000 title claims abstract description 60
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 16
- 239000003814 drug Substances 0.000 title claims abstract description 16
- 239000000203 mixture Substances 0.000 title claims abstract description 16
- 239000003963 antioxidant agent Substances 0.000 title claims abstract description 10
- 229940079593 drug Drugs 0.000 title abstract description 7
- 238000002360 preparation method Methods 0.000 title abstract description 3
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229960000282 metronidazole Drugs 0.000 claims abstract description 12
- 201000010099 disease Diseases 0.000 claims abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 11
- 230000003647 oxidation Effects 0.000 claims abstract description 9
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 9
- 108010052008 colla corii asini Proteins 0.000 claims description 10
- 230000001413 cellular effect Effects 0.000 claims description 4
- 241000252212 Danio rerio Species 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 13
- 238000002474 experimental method Methods 0.000 abstract description 11
- 230000009467 reduction Effects 0.000 abstract description 5
- 238000010171 animal model Methods 0.000 abstract description 4
- 210000001161 mammalian embryo Anatomy 0.000 abstract description 3
- 230000009261 transgenic effect Effects 0.000 abstract description 3
- 230000009471 action Effects 0.000 abstract description 2
- 230000008859 change Effects 0.000 abstract description 2
- 238000011534 incubation Methods 0.000 abstract description 2
- 230000000270 postfertilization Effects 0.000 abstract description 2
- 150000003254 radicals Chemical class 0.000 description 9
- 238000002073 fluorescence micrograph Methods 0.000 description 7
- 235000006708 antioxidants Nutrition 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 230000003064 anti-oxidating effect Effects 0.000 description 4
- 210000002257 embryonic structure Anatomy 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 241000283074 Equus asinus Species 0.000 description 2
- 108010059712 Pronase Proteins 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241001331845 Equus asinus x caballus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- OMTUBVCMHVLLLS-UHFFFAOYSA-N ethyl 2-aminobenzoate methanesulfonic acid Chemical compound CS(O)(=O)=O.CCOC(=O)C1=CC=CC=C1N OMTUBVCMHVLLLS-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- -1 rheumatoid arthritis Chemical class 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- ZMCBYSBVJIMENC-UHFFFAOYSA-N tricaine Chemical compound CCOC(=O)C1=CC=CC(N)=C1 ZMCBYSBVJIMENC-UHFFFAOYSA-N 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 108700024526 zebrafish sox32 Proteins 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
Abstract
The invention discloses application of a composition of donkey-hide gelatin and new donkey-hide gelatin in preparation of an antioxidant drug, the experimental method of the invention adopts 24hpf (duct post fertilization) skin fluorescence transgenic zebra fish as an experimental animal, the drug and an embryo are incubated for 24h, and after the incubation is finished, the change of the number of skin fluorescence points is observed under a fluorescence microscope. Experiments prove that the donkey-hide gelatin and new donkey-hide gelatin composition has a reversing effect on reduction of skin fluorescent spots of the zebra fish induced by metronidazole, and both the donkey-hide gelatin and the new donkey-hide gelatin composition have antioxidant activity under the conditions of proper action concentration and proportion. Experiments show that the composition of the donkey-hide gelatin and the new donkey-hide gelatin can be used for preparing antioxidant medicaments; in particular to a medicine for preparing diseases related to cell oxidation caused by metronidazole.
Description
Technical Field
The application relates to a new application of a donkey-hide gelatin composition, in particular to an application of a composition of donkey-hide gelatin and new donkey-hide gelatin in preparing an antioxidant drug.
Background
A radical is a particle with unpaired electrons. Because of the single number of electrons, it is very unstable, has high chemical reactivity, and can easily react with surrounding molecules, so that the stable molecules also become free radicals. This is repeated over and over again to derive a large number of free radicals. In general, life is not isolated from free radical activity. Our bodies move from inside to outside every moment, and the energy is burned at every moment, and the transporters responsible for transferring the energy are free radicals. When these free radicals, which help energy conversion, are enclosed in cells and cannot escape or cross, they are harmless to life. However, if the activity of the free radicals is out of control, beyond a certain amount, the normal order of life is destroyed and the disease may follow. Therefore, free radicals are known to be a double-edged sword, and many diseases are known to be caused by free radicals, such as rheumatoid arthritis, acute respiratory distress syndrome, AIDS, periodontal disease and the like.
Colla Corii Asini is solid gum prepared from dry or fresh skin of Equus asinus L. Has effects in replenishing blood, nourishing yin, moistening dryness, and stopping bleeding. Modern pharmacological research shows that the donkey-hide gelatin has the effects of enriching blood, stopping bleeding, enhancing immunity, resisting radiation, inhibiting tumor, resisting fatigue, preventing osteoporosis, promoting bone healing and the like.
The medicinal history of pigskin gelatin has been started before now. Posthan zhangzhongjing "typhoid treatise on shaoyin chapter" cloud: shaoyin disease, sore throat, fullness in chest, restlessness and restlessness, which is cooked in pork skin soup. "Yi Zong jin Jian" is a prescription: the "pig skin" is also the skin of the leather. "Li Shizhen" Ben Cao gang mu "cloud: from October to March, cattle, buffalo and donkey hide are used for the first time and pig, horse, mule and camel hide are used for the second time. "
In the prior art, the donkey-hide gelatin is recorded to have an anti-oxidation effect, and a reference is made to a paper (research on the anti-oxidation effect and mechanism of the donkey-hide gelatin cake and the main raw material of the donkey-hide gelatin [ D ]. Zhejiang university, 2019 ]), but in actual use, the anti-oxidation effect of the donkey-hide gelatin is limited, and the application of a combination of the donkey-hide gelatin and new donkey-hide gelatin in preparing an anti-oxidation medicine is not disclosed in the prior art.
Disclosure of Invention
In order to solve the problems, the application provides an application of a composition of donkey-hide gelatin and new donkey-hide gelatin in preparing an antioxidant drug.
A large number of experiments show that the donkey-hide gelatin and new donkey-hide gelatin composition has an antioxidant effect on cell oxidation caused by metronidazole.
Preferably, the disease associated with cellular oxidation is a disease associated with cellular oxidation due to the use of metronidazole.
Preferably, the donkey-hide gelatin and the new donkey-hide gelatin are included in effective dose.
Preferably, the weight ratio of the donkey-hide gelatin to the new donkey-hide gelatin is 1: 10-10: 1.
Preferably, the weight ratio of the donkey-hide gelatin to the new donkey-hide gelatin is 1: 1.
The experimental method adopts the skin fluorescence transgenic zebra fish which develops 24hpf (liver post fertilization) as an experimental animal, the drug and the embryo are incubated for 24 hours, and after the incubation is finished, the change of the number of the skin fluorescence points is observed under a fluorescence microscope and is analyzed statistically. Experiments prove that the donkey-hide gelatin and new donkey-hide gelatin composition has a reversing effect on reduction of skin fluorescent spots of the zebra fish induced by metronidazole, and both the donkey-hide gelatin and the new donkey-hide gelatin composition have antioxidant activity under the conditions of proper action concentration and proportion.
In conclusion, the combination of the donkey-hide gelatin and the new donkey-hide gelatin can be used for preparing antioxidant medicaments; in particular to a medicine for preparing diseases related to cell oxidation caused by metronidazole.
Drawings
The accompanying drawings, which are included to provide a further understanding of the application and are incorporated in and constitute a part of this application, illustrate embodiment(s) of the application and together with the description serve to explain the application and not to limit the application. In the drawings:
fig. 1 is a fluorescence micrograph of example, in which fig. a is a fluorescence micrograph of control 1, fig. B is a fluorescence micrograph of control 2, fig. C is a fluorescence micrograph of control 3, fig. D is a fluorescence micrograph of example 1, fig. E is a fluorescence micrograph of example 2, and fig. F is a fluorescence micrograph of example 3.
Detailed Description
Example (b): evaluation experiment of antioxidant activity of donkey-hide gelatin and novel donkey-hide gelatin composition
The experimental method used in this example was:
the skin fluorescent zebra fish which develops for 24h is taken as an experimental animal, and the outer layer of the embryo of the zebra fish is stripped off by using 1mg/mL pronase. Randomly distributing embryos without the egg membranes, setting 2 compound holes for each group of experiments with 10 embryos, and averaging the experimental results after each group of experiments are repeated for three times. All of the above embryos were placed in a constant temperature incubator at 28.5 ℃, treated with each experimental solution in table 1 for 24 hours, anesthetized with ethyl m-aminobenzoate mesylate (MS222), and photographed by observation under a fluorescence microscope. The number of skin fluorescent spots of the zebra fish was counted using Imagepro-plus software, and the data were statistically analyzed using GraphPad software to evaluate the antioxidant activity of the samples.
The experimental apparatus used in this example includes: model SZX16 fluorescent microscope and DP2-BSW image acquisition system (Olympus, Japan); an inverted microscope model X51 (Olympus, japan); forma 3111 type water jacket CO2Incubators (Forma corporation, usa); zebra fish breeding equipment (Beijing Aisheng science and technology company).
The experimental drugs used in this example include: colla Corii Asini and new colla Corii Asini samples are provided by Fupai colla Corii Asini company; metronidazole and vitamin C were purchased from shanghai bio-chemical company; pronase and ethyl aminobenzoate mesylate were both obtained from sigma. Grinding a donkey-hide gelatin sample into powder, and dissolving the powder with sterile water; both metronidazole and vitamin C are dissolved in sterile water.
The experimental animals used in this example include: the skin fluorescent transgenic zebra fish and the AB line zebra fish are provided by a zebra fish drug screening platform of biological research institute of academy of sciences in Shandong province.
The specific implementation conditions are as follows:
TABLE 1 detailed conditions and results of the experiments in the examples
Wherein the control group 1 is a blank control group, the control group 2 is a metronidazole modeling group, and the control group 3 is a positive control group.
As can be seen from the experimental results in table 1 and fig. 1, the zebra fish of the control group 1 and the zebra fish of the control group 2 are normally developed, but the number of fluorescent spots on the skin of the zebra fish of the control group 2 is obviously reduced compared with the control group 1, which obviously indicates that under the influence of metronidazole, the cells on the skin of the zebra fish are oxidized; the zebra fish in examples 1-7 developed normally, but the number of skin fluorescent spots was increased compared with the control group 2, indicating that the combination of donkey-hide gelatin and new donkey-hide gelatin has a significant antioxidant effect.
From the experimental data in table 1, in the concentration range of 10-100 μ g/mL, as the concentration of the donkey-hide gelatin and the new donkey-hide gelatin composition increases, the number of the fluorescent spots on the skin of the zebra fish also increases, and shows a good increasing relationship, as shown in fig. 1. The reversing effect on the reduction of the number of fluorescent spots on the skin of the zebra fish can be achieved when the mass ratio of the donkey-hide gelatin to the new donkey-hide gelatin is 1: 10-10: 1, and the reversing effect is better especially when the mass ratio of the donkey-hide gelatin to the new donkey-hide gelatin is 1: 1.
Compared with the comparative example 1, the comparative example 2 and the example 3, the reversing effect of the combination of the donkey-hide gelatin and the new donkey-hide gelatin on the reduction of the skin fluorescent spots of the zebra fish is far better than the reversing effect of the combination of the donkey-hide gelatin and the new donkey-hide gelatin on the reduction of the skin fluorescent spots of the zebra fish.
In conclusion, the combination of the donkey-hide gelatin and the new donkey-hide gelatin can be used for preparing antioxidant medicaments; in particular to a medicine for preparing diseases related to cell oxidation caused by metronidazole.
The embodiments in the present specification are described in a progressive manner, and the same and similar parts among the embodiments are referred to each other, and each embodiment focuses on the differences from the other embodiments. In particular, for the system embodiment, since it is substantially similar to the method embodiment, the description is simple, and for the relevant points, reference may be made to the partial description of the method embodiment.
The above description is only an example of the present application and is not intended to limit the present application. Various modifications and changes may occur to those skilled in the art. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present application should be included in the scope of the claims of the present application.
Claims (6)
1. Application of a composition of colla Corii Asini and new colla Corii Asini in preparing antioxidant medicine is provided.
2. Application of a composition of colla Corii Asini and new colla Corii Asini in preparing antioxidant medicine for preventing or treating diseases related to cell oxidation is provided.
3. The use according to claim 2, wherein the disease associated with cellular oxidation is a disease associated with cellular oxidation due to the use of metronidazole.
4. Use according to any one of claims 1 to 3, characterized in that: comprises effective dose of colla Corii Asini and new colla Corii Asini.
5. Use according to claim 4, characterized in that: the weight ratio of the donkey-hide gelatin to the new donkey-hide gelatin is 1: 10-10: 1.
6. Use according to claim 5, characterized in that: the weight ratio of the donkey-hide gelatin to the new donkey-hide gelatin is 1: 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911221783.5A CN110840916A (en) | 2019-12-03 | 2019-12-03 | Application of composition of donkey-hide gelatin and new donkey-hide gelatin in preparation of antioxidant drugs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911221783.5A CN110840916A (en) | 2019-12-03 | 2019-12-03 | Application of composition of donkey-hide gelatin and new donkey-hide gelatin in preparation of antioxidant drugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110840916A true CN110840916A (en) | 2020-02-28 |
Family
ID=69607377
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911221783.5A Pending CN110840916A (en) | 2019-12-03 | 2019-12-03 | Application of composition of donkey-hide gelatin and new donkey-hide gelatin in preparation of antioxidant drugs |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110840916A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111514167A (en) * | 2020-05-09 | 2020-08-11 | 北京航空航天大学 | Application of donkey-hide gelatin in product for relieving oxidative stress injury of cells |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102499376A (en) * | 2011-12-29 | 2012-06-20 | 山东东阿阿胶股份有限公司 | Active small-molecule donkey-hide gelatin mixture and preparation method and application thereof |
| CN105726572A (en) * | 2016-03-03 | 2016-07-06 | 东阿阿胶股份有限公司 | Application of donkey-hide gelatins to preparation of medicament or healthcare product for treating respiratory injury caused by fine air particulate matters |
| CN106236777A (en) * | 2016-08-04 | 2016-12-21 | 山东福胶集团东阿镇阿胶有限公司 | A kind of new Colla Corii Asini |
| CN107519217A (en) * | 2017-08-30 | 2017-12-29 | 北京化工大学 | A kind of high anti-oxidation anti-cancer composition of hydrolysate containing donkey-hide gelatin and ginkgo biloba p.e and its preparation method and application |
-
2019
- 2019-12-03 CN CN201911221783.5A patent/CN110840916A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102499376A (en) * | 2011-12-29 | 2012-06-20 | 山东东阿阿胶股份有限公司 | Active small-molecule donkey-hide gelatin mixture and preparation method and application thereof |
| CN105726572A (en) * | 2016-03-03 | 2016-07-06 | 东阿阿胶股份有限公司 | Application of donkey-hide gelatins to preparation of medicament or healthcare product for treating respiratory injury caused by fine air particulate matters |
| CN106236777A (en) * | 2016-08-04 | 2016-12-21 | 山东福胶集团东阿镇阿胶有限公司 | A kind of new Colla Corii Asini |
| CN107519217A (en) * | 2017-08-30 | 2017-12-29 | 北京化工大学 | A kind of high anti-oxidation anti-cancer composition of hydrolysate containing donkey-hide gelatin and ginkgo biloba p.e and its preparation method and application |
Non-Patent Citations (3)
| Title |
|---|
| 张闽等: "酶解明胶制备抗氧化多肤清除DPPH.自由基的响应面优化", 《食品工业》 * |
| 邸志权等: "阿胶补血、抗疲劳以及止血作用研究", 《药物评价研究》 * |
| 靳士英: "《抗衰老保健中药小百科》", 31 January 2003, 人民军医出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111514167A (en) * | 2020-05-09 | 2020-08-11 | 北京航空航天大学 | Application of donkey-hide gelatin in product for relieving oxidative stress injury of cells |
| CN111514167B (en) * | 2020-05-09 | 2022-05-24 | 北京航空航天大学 | Application of donkey-hide gelatin in product for relieving oxidative stress injury of cells |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Berrocoso et al. | Effect of in ovo injection of raffinose on growth performance and gut health parameters of broiler chicken | |
| SE201646C1 (en) | ||
| CN1170435A (en) | Regulation of neural stem cell proliferation | |
| EP1862081A1 (en) | Feed composition and method of breeding animal | |
| CN110840916A (en) | Application of composition of donkey-hide gelatin and new donkey-hide gelatin in preparation of antioxidant drugs | |
| Al-Zghoul et al. | Thermal manipulation mid-term broiler chicken embryogenesis: effect on muscle growth factors and muscle marker genes | |
| Semenenko et al. | Possibilities of using natural aluminosilicates in the development of medicines at hepatosis in poultry | |
| CN110201142A (en) | A kind of compound preparation and preparation method thereof for preventing and treating hen salpingitis | |
| DE3600083A1 (en) | USE OF INTERFERON TO IMPROVE THE EFFECTIVENESS OF THE FORAGE AND TO INFLUENCE THE APPETITE OF ANIMALS | |
| CN115316339B (en) | Method for improving oxidation resistance and nutrition transfer capacity of placenta tissue of female livestock | |
| EA031870B1 (en) | Antiviral effects of narasin in swine feed | |
| Banes et al. | Collagen biochemistry of osteopetrotic bone: I. Quantitative changes in bone collagen cross-links in virus-induced avian osteopetrosis | |
| CN110742907A (en) | Application of composition of donkey-hide gelatin and new donkey-hide gelatin in preparation of anti-aging drugs | |
| RU2351151C1 (en) | Method of increasing resistance of organism of broilers | |
| CN110693915A (en) | Application of donkey-hide gelatin and novel donkey-hide gelatin composition in preparation of medicines for preventing or treating diseases related to leucopenia | |
| RU2697156C2 (en) | Method for stimulation of embryogenesis of chicken embryos | |
| Houlihan et al. | Nerve growth-promoting properties of 1, 1, 3-tricyano-2-amino-1-propene | |
| El‐naseery et al. | Species‐specific differences of the avian oesophagus: Histological and Ultrastructural study | |
| RU2270580C2 (en) | Method for reducing lead content in hen's body | |
| King | The feeding of copper sulphate to ducklings | |
| RU2149602C1 (en) | Method of aerosol treatment of chicken | |
| RU2396947C2 (en) | Method for reduction of negative impact of technology stress on young cattle | |
| Elokil et al. | Study the effect of microinjection of Zn, Fe, and Cu loaded in montmorillonite on development activities in fertilized chicken eggs | |
| Brunst et al. | Influence of local x-ray treatment on development of jaws in young axolotl (Siredon mexicanum) | |
| Mourtzi et al. | Enhancement of endogenous midbrain neurogenesis by microneurotrophin BNN-20 after neural progenitor grafting in a mouse model of nigral degeneration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200228 |